MDXG Stock Analysis: Buy, Sell, or Hold?
MDXG - MiMedx Group, Inc
$4.27
0.14 (3.39%)
▲
5d:
+0.23%
30d:
+8.1%
90d:
+16.03%
BUY
MODERATE Confidence
Analysis Updated: Aug 3, 2026 12:00 AM ET
Earnings: Jul 29, 2026
0d
Get Alerted When MDXG Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: MDXG shows positive signals but monitor for confirmation. Market pricing in 13.3% decline. Moderate conviction.
💡 BUY OPPORTUNITY: MDXG shows positive signals but monitor for confirmation. Market pricing in 13.3% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$8.41
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$5.22
18.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: MDXG is currently trading at $4.27, which is considered slightly high relative to its 30-day fair value range of $3.99 to $4.31. From a valuation perspective, the stock is trading at a discount (Forward PE: 17.8) compared to its historical average (27.3). Remarkably, the market is currently pricing in an annual earnings decline of 13.3% over the next few years. This pessimistic expectation contrasts with the company's recent 99.5% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, MDXG is showing sideways momentum. Immediate support is located at $3.76, while resistance sits at $4.49. The stock is showing strong short-term momentum, up 3.4% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.60 (+54.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, MDXG is showing sideways momentum. Immediate support is located at $3.76, while resistance sits at $4.49. The stock is showing strong short-term momentum, up 3.4% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.60 (+54.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$3.99 -
$4.31
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
70.0%
All Signals
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.4%)
- BULLISH: Trading 54.6% below Wall St target ($6.60)
Trading Range Analysis
30-Day Trading Range
$3.99 -
$4.31
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$3.76
Resistance Level
$4.49
Current Trend
Sideways
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
17.79
Wall Street Target
$6.60
(+54.6%)
Revenue Growth (YoY)
-34.7%
Earnings Growth (YoY)
99.5%
Profit Margin
1.8%
Valuation Discount vs History
-13.3% cheaper
PE vs Historical
17.8 vs 27.3
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-13.3%
(market-implied from PE analysis)
1-Year Target
$3.84
(-10%)
2-Year Target
$3.46
(-19%)
3-Year Target
$3.11
(-27%)
3-Yr Target (if PE normalizes)
(PE: 18→27)
$4.78
(+12%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (20x PE), but valuation improves significantly next year (18x PE) as earnings recover.
Forward PE: 19.53 | Forward EPS (Implied): $0.22
Bull Case
$5.16
(+21%)
Analyst growth 15.0%, PE expands to 20.5
Base Case
$4.27
(0%)
Market implied 0.0%, PE stable at 19.5
Bear Case
$3.27
(-24%)
Severe decline -15.0%, PE contracts to 17.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 17.8 to 27.3
Stabilization Target:
$6.55
(+53.4%)
PE Expansion Potential:
+53.4%
Share & Embed Analysis
Last updated: August 04, 2026 8:27 AM ET
Data refreshes hourly during market hours. Next update: 9:27 AM
Data refreshes hourly during market hours. Next update: 9:27 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MDXG showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$89 | 59 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 56 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 53 HOLD |
|
ARVN
Arvinas Inc |
BUY
21 analysts |
$15 | 51 HOLD |
